This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Non-steroidal anti-inflammatory drugs in RA

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NSAIDs are used to control the synovitis.

  • NSAID use in RA(1):
    • all NSAIDs and selective COX-2 inhibitors can adversely affect renal function, promote fluid retention and exacerbate hypertension
    • newer selective COX-2 inhibitors have been associated with an excess of cardiovascular events which has led to the withdrawal of rofecoxib and significant changes to the labelling and use of celecoxib and etoricoxib
    • the use of non-selective (ns) NSAIDs/selective COX-2 inhibitors should be considered carefully in patients with RA
      • continued requirement for nsNSAID/selective COX-2 inhibitor therapy in some patients may indicate that further adjustment to their disease-modifying anti-rheumatic drug (DMARD) therapy is indicated to control inflammation better
    • the NSAID/selective COX-2 inhibitor dose should be reviewed and the lowest effective dose should be used for the shortest period of time

Notes (1):

  • some patients with RA will additionally be on treatment with low-dose aspirin (either because of established cardiovascular disease or a primary prevention measure) as well as an NSAID
    • co-prescription of ibuprofen and low-dose aspirin should be avoided
    • the majority of patients on aspirin plus a NSAID will also require some form of gastroprotection
  • NICE state that (2):
    • analgesics should be offered (for example, paracetamol, codeine or compound analgesics) to people with RA whose pain control is not adequate, to potentially reduce their need for long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors
    • oral NSAIDs/COX-2 inhibitors should be used at the lowest effective dose for the shortest possible period of time
    • when offering treatment with an oral NSAID/COX-2 inhibitor
      • first choice should be either a standard NSAID or a COX-2 inhibitor (other than etoricoxib 60 mg)
        • in either case, these should be co prescribed with a proton pump inhibitor (PPI)
    • all oral NSAIDs/COX-2 inhibitors have analgesic effects of a similar magnitude but vary in their potential gastrointestinal, liver and cardio-renal toxicity; therefore, when choosing the agent and dose, healthcare professionals should take into account individual patient risk factors, including age
    • if a person with RA needs to take low-dose aspirin, healthcare professionals should consider other analgesics before substituting or adding an NSAID or COX-2 inhibitor (with a PPI) if pain relief is ineffective or insufficient
    • if NSAIDs or COX-2 inhibitors are not providing satisfactory symptom control, review the disease-modifying or biological drug regimen

Reference:

  1. ARC. Management of cardiovascular disease in RA and SLE. Hands On 2006;8:1-4.
  2. NICE (February 2009). Rheumatoid arthritis- The management of rheumatoid arthritis in adults

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.